Israel's Oramed ($ORMP) won a patent from the European Union for its oral insulin pill, giving the Jerusalem company a potential foothold in the diabetes market estimated to be worth about $14 billion by 2017, according to analysts. The patent covers Oramed's process for the oral administration of proteins. The company's main insulin pill is currently in Phase II trials for Type 2 diabetes, and its oral exanatide capsule, also for Type 2, is in early clinical stages. Release